Table 2.
Changes in area power (μV2) of the kainate-induced oscillatory activity, 60 min after the application of various antagonists and modulators of neural transmission
| Antagonist | Area power in the presence of 100 nm kainate at 0 min | Area power in the presence of 100 nm kainate 60 min after application of the antagonist | Recovery after 60 min in the presence of 100 nm kainate alone |
|---|---|---|---|
| NBQX (n= 6) | 55.4 ± 41.2 | 17.2 ± 9.4* | 39.5 ± 34.1 |
| d-AP5 (n= 9) | 26.3 ± 17.1 | 30.4 ± 23.0 | — |
| SYM 2206 (n= 13) | 84.5 ± 110.8 | 61.0 ± 39.6 | — |
| Bicuculline (n= 7) | 64 ± 88.2 | 36.3 ± 40.2* | 56.7 ± 77.2 |
| CGP55845 (n= 4) | 23.6 ± 20.8 | 24.9 ± 20.6 | — |
| Diazepam (n= 4) | 2.9 ± 0.7 | 3.1 ± 0.9 | — |
| Atropine (n= 6) | 8.7 ± 3.2 | 9.9 ± 3.4 | — |
| Mecamylamine (n= 3) | 77.9 ± 15.5 | 77.2 ± 14.1 | — |
| Carbenoxolone (n= 5) | 21.3 ± 13.7 | 4.4 ± 3.9 | — |
| Octanol (n= 3) | 10.8 ± 8.5 | 3.3 ± 2.9 | — |
Values are mean ±s.d.*Statistically significant change (P < 0.05) from the previous value (see text for details of the statistical tests used).